AMENDMENTS TO THE CLAIMS

1-5. (Cancelled).

6. (Previously Presented) An adhesive preparation for percutaneous absorption consisting essentially of a base polymer, norethisterone, estradiol, a softener, and an adhesive resin, wherein

the base polymer consists essentially of a styrene-isoprene-styrene block copolymer;

the norethisterone is dissolved in the adhesive preparation without crystallization in the absence of hexylene glycol;

the estradiol is not more than 2 % by weight based on the adhesive preparation;

the softener is selected from liquid paraffin, polybutene, castor oil, cottonseed oil, palm oil, coconut oil, and processed oil; and

the adhesive resin is selected from alicyclic saturated hydrocarbon resins, rosin ester, hydrogen alicyclic hydrocarbon, terpene-based hydrogenated resin, and hydrogenated rosin ester.

7. (Previously Presented) The adhesive preparation for percutaneous absorption according to claim 6, wherein norethisterone is dissolved in the amount showing the releasing rate in water being not less than 30% after 25 hours determined by the drug releasing test according to the cylinder method described in the USP Drug release Test under the following conditions:

Test solution 900 ml water;

Temperature of test solution 32.0 ± 0.5°C;

Distance from the lowest end of cylinder to the basal inner plane of vessel 25 ± 2 mm; and

Revolution of cylinder 50 rpm.

8-9. (Cancelled).

10. (Currently Amended) The adhesive preparation for percutaneous absorption according to claim 6 or claim 7~~any of claims 6 – 9~~, wherein an amount of norethisterone to be dissolved is in the amount not more than 2 % by weight based on the whole ~~base~~composition.

11. (Currently Amended) The adhesive preparation for percutaneous absorption according to ~~any of claims 6 – 9~~claim 6 or claim 7, wherein the ~~adhesive preparation containing a~~ styrene-isoprene-styrene block copolymer ~~comprises~~ is 10 – 30 % by weight of ~~a styrene-isoprene-styrene block copolymer~~the adhesive preparation, ~~10 – 60 % by weight of a~~ the softener is 10 – 60 % by weight of the adhesive preparation, and ~~20 – 60 % by weight of an~~ the adhesive resin is 20 – 60 % by weight of the adhesive preparation~~based on the whole base~~.

12. (Currently Amended) ~~The~~ An adhesive preparation for percutaneous absorption consisting essentially of a base polymer, norethisterone, estradiol, a softener, ~~according to any one of claims 6 – 9, wherein the adhesive preparation further consists of~~ an antioxidant and an adhesive resin, wherein

the base polymer consists essentially of a styrene-isoprene-styrene block copolymer;

the norethisterone is dissolved in the adhesive preparation without crystallization in the absence of hexylene glycol;

the estradiol is not more than 2 % by weight based on the adhesive preparation;

the softener is selected from liquid paraffin, polybutene, castor oil, cottonseed oil, palm oil, coconut oil, and processed oil; and

the adhesive resin is selected from alicyclic saturated hydrocarbon resins, rosin ester, hydrogen alicyclic hydrocarbon, terpene-based hydrogenated resin, and hydrogenated rosin ester.

13. (Previously Presented) The adhesive preparation for percutaneous absorption according to claim 12, wherein the antioxidant is dibutylhydroxytoluene.